Guangdong-Hong Kong-Macau Greater Bay Area

The 23rd Hong Kong Forum gathered 100 global business leaders from Federation of Hong Kong Business Associations Worldwide to explore the latest opportunities in Hong Kong

Retrieved on: 
Thursday, December 1, 2022

The Forum, organised by the Hong Kong Trade Development Council (HKTDC), serves as the annual flagship event of the Federation of Hong Kong Business Associations Worldwide (FHKBAW).

Key Points: 
  • The Forum, organised by the Hong Kong Trade Development Council (HKTDC), serves as the annual flagship event of the Federation of Hong Kong Business Associations Worldwide (FHKBAW).
  • The two-day event, which concluded yesterday, welcomed more than 180 participants, including 100 global business leaders, in-person.
  • Mark Staublin, President of Hong Kong Business Association of the Midwest mentioned "This is my first visit to Hong Kong after two years.
  • With the help of the Hong Kong Trade Development Council (HKTDC), these Associations formed the Federation of Hong Kong Business Associations Worldwide in November 2000.

Guangzhou Nansha Tax Incentives: A Magnet for Hong Kong and Macao Residents and the Encouraged Businesses and Industries

Retrieved on: 
Wednesday, November 30, 2022

Under these measures, for Hong Kong and Macao residents working in Nansha, the IIT burden exceeding that in the two special administrative regions (SARs) will be exempted.

Key Points: 
  • Under these measures, for Hong Kong and Macao residents working in Nansha, the IIT burden exceeding that in the two special administrative regions (SARs) will be exempted.
  • It will help create a favorable business and living environment in Nansha where the IIT policies align with those of Hong Kong and Macao and facilitate Hong Kong and Macao residents in the establishment of their own businesses or simply gaining employment in Nansha.
  • Zhaoke Ophthalmology, a biomedical company founded in Nansha, had only one Hong Kong executive based in Nansha before the Plan of Guangzhou Nansha was implemented.
  • Given that Hong Kong residents who work in Nansha can now enjoy tax rebates in line with the Hong Kong tax system, more overseas executives are forecast to be based in Nansha.

Guangzhou Nansha Tax Incentives: A Magnet for Hong Kong and Macao Residents and the Encouraged Businesses and Industries

Retrieved on: 
Wednesday, November 30, 2022

It will help create a favorable business and living environment in Nansha where the IIT policies align with those of Hong Kong and Macao and facilitate Hong Kong and Macao residents in the establishment of their own businesses or simply gaining employment in Nansha.

Key Points: 
  • It will help create a favorable business and living environment in Nansha where the IIT policies align with those of Hong Kong and Macao and facilitate Hong Kong and Macao residents in the establishment of their own businesses or simply gaining employment in Nansha.
  • The associated benefits generated in the development of the Greater Bay Area will be shared by more Hong Kong and Macao residents, according to Nansha District People's Government of Guangzhou City.
  • Zhaoke Ophthalmology, a biomedical company founded in Nansha, had only one Hong Kong executive based in Nansha before the Plan of Guangzhou Nansha was implemented.
  • Given that Hong Kong residents who work in Nansha can now enjoy tax rebates in line with the Hong Kong tax system, more overseas executives are forecast to be based in Nansha.

Regina Miracle Fiscal 2023 Interim Results Revenue Reaches HK$4.61 Billion; Hitting a Record High for the Period, Net Profit Rose 23.1% to HK$313 Million

Retrieved on: 
Tuesday, November 29, 2022

Its total cash on hand was approximately HK$872.1 million as at 30 September 2022 (31 March 2022: approximately HK$995.0 million).

Key Points: 
  • Its total cash on hand was approximately HK$872.1 million as at 30 September 2022 (31 March 2022: approximately HK$995.0 million).
  • So that to enable Regina Miracle to grasp the opportunities for market penetration amid the industry consolidation."
  • This business segment contributed approximately HK$1,483.7 million in revenue during the Period (1HF2022: HK$1,036.4 million), a 43.2% year-on-year increase, accounting for 32.2% of total revenue.
  • Segmental gross profit was approximately HK$358.0 million and gross profit margin was 24.1% (1HF2022: HK$243.4 million and 23.5%, respectively).

IFF Annual Meeting to open in Guangzhou

Retrieved on: 
Tuesday, November 29, 2022

GUANGZHOU, China, Nov. 29, 2022 /PRNewswire/ -- The 19th International Finance Forum Annual Meeting will take place between December 2 to 4 in Guangzhou with packed meetings and events centred on the theme of"the Ever-Changing World: Reshaping Our Shared Future".

Key Points: 
  • GUANGZHOU, China, Nov. 29, 2022 /PRNewswire/ -- The 19th International Finance Forum Annual Meeting will take place between December 2 to 4 in Guangzhou with packed meetings and events centred on the theme of"the Ever-Changing World: Reshaping Our Shared Future".
  • The Meeting is co-organised by the International Finance Forum and the People's Government of Guangzhou Municipality.
  • This year's Annual Meeting will also play a key role in promoting Guangzhou's open market, accelerating the growth of the Greater Bay Area and the internationalisation of its financial market."
  • The IFF is to release the Global Finance and Development Report, its annual report on global economy as well as China's economic outlook in 2023.

IFF Annual Meeting to open in Guangzhou

Retrieved on: 
Tuesday, November 29, 2022

GUANGZHOU, China, Nov. 28, 2022 /PRNewswire/ -- The 19th International Finance Forum Annual Meeting will take place between December 2 to 4 in Guangzhou with packed meetings and events centred on the theme of"the Ever-Changing World: Reshaping Our Shared Future".

Key Points: 
  • GUANGZHOU, China, Nov. 28, 2022 /PRNewswire/ -- The 19th International Finance Forum Annual Meeting will take place between December 2 to 4 in Guangzhou with packed meetings and events centred on the theme of"the Ever-Changing World: Reshaping Our Shared Future".
  • The Meeting is co-organised by the International Finance Forum and the People's Government of Guangzhou Municipality.
  • This year's Annual Meeting will also play a key role in promoting Guangzhou's open market, accelerating the growth of the Greater Bay Area and the internationalisation of its financial market."
  • The IFF is to release the Global Finance and Development Report, its annual report on global economy as well as China's economic outlook in 2023.

Chindata Group announced 2022 Q3 financial report: revenue in the first nine months of 2022 has surpassed that of the full year of 2021

Retrieved on: 
Monday, November 28, 2022

Revenue was RMB1,202.7 million in the third quarter of 2022, which was a 62.4% year over year ("YoY") growth.

Key Points: 
  • Revenue was RMB1,202.7 million in the third quarter of 2022, which was a 62.4% year over year ("YoY") growth.
  • Adjusted EBITDA in the third quarter of 2022 increased by 66.8% YoY to RMB614.5 million, with a margin of 51.1%.
  • Revenue in the first nine months of 2022 has surpassed that of the full year of 2021.
  • Revenue in the first nine months of 2022 has surpassed the revenue in the full year of 2021, and we are raising our full year guidance for the second time this year.

JBM Healthcare Announces FY2023 Interim Results

Retrieved on: 
Friday, November 25, 2022

HONG KONG, Nov 25, 2022 - (ACN Newswire) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Group"; Stock Code: 2161), a leading branded healthcare products marketer and distributor in Hong Kong, has announced today the interim results of the Group for the six months ended 30 September 2022 (the "Reporting Period").

Key Points: 
  • HONG KONG, Nov 25, 2022 - (ACN Newswire) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Group"; Stock Code: 2161), a leading branded healthcare products marketer and distributor in Hong Kong, has announced today the interim results of the Group for the six months ended 30 September 2022 (the "Reporting Period").
  • The Board declares the payment of an interim dividend for the six months ended 30 September 2022 of HK0.5 cent per share.
  • About JBM (Healthcare) Limited (Stock Code: 2161)
    JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries.
  • JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021.

China Wantian Holdings Completes the Acquisition of Domestic Fresh Food Supply Chain Service Provider

Retrieved on: 
Friday, November 25, 2022

It marks the Group's expansion of its fresh food ingredient business into the Guangdong-Hong Kong-Macao Greater Bay Area (the "Greater Bay Area") market.

Key Points: 
  • It marks the Group's expansion of its fresh food ingredient business into the Guangdong-Hong Kong-Macao Greater Bay Area (the "Greater Bay Area") market.
  • It sources live cattle from Inner Mongolia and distributes them to slaughterhouses in the Greater Bay Area.
  • Looking ahead, China Wantian Holdings aims to enhance the diversity of its development strategies by expanding its businesses.
  • The Group is principally engaged in food supply, catering chain and environmental protection and technology.

XtalPi and CK Life Sciences to collaborate in AI-empowered tumour vaccine research and development, opening a new paradigm for scientific innovation

Retrieved on: 
Friday, November 25, 2022

SHENZHEN & HONG KONG, China, Nov. 24, 2022 /PRNewswire/ -- XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide.

Key Points: 
  • XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types.
  • Currently, the design and preclinical development process for tumour vaccines is complex and lengthy, hindering the efficiency and success rate of tumour vaccine research and development.
  • We believe the AI cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to progress vaccine research and development and fast-track key development milestones for cancer vaccines.
  • Dr. Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, comments: "The R&D of tumour vaccines is one of the key development directions of CK Life Sciences.